Mereo BioPharma (MREO) Current Assets (2017 - 2026)

Mereo BioPharma (MREO) has 10 years of Current Assets data on file, last reported at $40.0 million in Q1 2026.

• Current Assets for Q1 2026 came in at $40.0 million, down 40.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $40.0 million (down 40.16% YoY), and the FY2025 annual result was $45.0 million, down 39.78% from the prior year.
• Current Assets slipped to $40.0 million in Q1 2026 per MREO's latest filing, from $45.0 million in the prior quarter.
• Over five years, Current Assets peaked at $93.9 million in Q2 2024 and troughed at $40.0 million in Q1 2026.
• A 5-year average of $64.7 million and a median of $63.8 million in 2023 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2025: Current Assets slumped 45.57% in 2022, then advanced 25.05% in 2025.
• A 5-year view of Current Assets shows it stood at $72.9 million in 2022, then decreased by 12.51% to $63.8 million in 2023, then grew by 17.26% to $74.8 million in 2024, then plunged by 39.78% to $45.0 million in 2025, then declined by 11.08% to $40.0 million in 2026.
• Business Quant data shows MREO's Current Assets at $40.0 million in Q1 2026, $45.0 million in Q4 2025, and $52.4 million in Q3 2025.